Fig. 1From: EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitorsPatient selection based on study inclusion/exclusion criteria.EGFR: epidermal growth factor receptor; LOT: line of therapy; NSCLC: non-small cell lung cancer; TKI: tyrosine kinase inhibitor.a Patients receiving multiple EGFR-TKIs in the same line of therapy on or after November 1, 2015 were excluded. This includes patients who started osimertinib plus a first- or second-generation EGFR-TKI or ≥ 2 first- or second-generation EGFR-TKIs.Back to article page